XML 58 R27.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Revenue (Tables)

6 Months Ended

Dec. 31, 2019

Revenue From Contract With Customer [Abstract]

Composition of Total Revenue by Product and by U.S versus Rest of World

The following table presents detail regarding the composition of our total revenue by product and by U.S versus rest of world, “RoW”:

		Three months ended December 31,
		2019												2018
(In millions)		U.S.				RoW				Total				U.S.				RoW				Total
Molecular diagnostic revenues:
Hereditary Cancer Testing		$	112.9			$	4.8			$	117.7			$	123.4			$	3.3			$	126.7
GeneSight			22.5				—				22.5				24.0				—				24.0
Prenatal			16.3				0.1				16.4				31.2				—				31.2
Vectra			10.3				—				10.3				11.8				—				11.8
Prolaris			6.7				0.1				6.8				6.1				—				6.1
EndoPredict			0.5				2.1				2.6				0.4				1.8				2.2
Other			4.8				—				4.8				0.7				0.3				1.0
Total molecular diagnostic revenue			174.0				7.1				181.1				197.6				5.4				203.0
Pharmaceutical and clinical service revenue			8.3				5.8				14.0				8.2				5.6				13.8
Total revenue		$	182.3			$	12.9			$	195.1			$	205.8			$	11.0			$	216.8

		Six months ended December 31,
		2019												2018
(In millions)		U.S.				RoW				Total				U.S.				RoW				Total
Molecular diagnostic revenues:
Hereditary Cancer Testing		$	213.5			$	8.7			$	222.2			$	237.0			$	6.1			$	243.1
GeneSight			45.2				—				45.2				53.2				—				53.2
Prenatal			39.8				0.1				39.9				49.3				—				49.3
Vectra			21.4				—				21.4				24.8				—				24.8
Prolaris			13.2				0.1				13.3				12.3				—				12.3
EndoPredict			0.9				3.9				4.8				0.7				3.9				4.6
Other			6.2				0.1				6.3				4.4				0.3				4.7
Total molecular diagnostic revenue			340.2				12.9				353.1				381.7				10.3				392.0
Pharmaceutical and clinical service revenue			16.8				11.6				28.3				15.8				11.3				27.1
Total revenue		$	357.0			$	24.5			$	381.4			$	397.5			$	21.6			$	419.1

Reconciliation of Deferred Revenue Balances

A reconciliation of the beginning and ending balances of deferred revenue is shown in the table below:

		Six months ended
		December 31,
		2019				2018
Deferred revenue - beginning balance		$	2.2			$	2.6
Revenue recognized			(1.1	)			(2.6	)
Prepayments			2.5				2.4
Deferred revenue - Ending Balance		$	3.6			$	2.4

X

- Definition

Tabular disclosure of contract balances and changes in contract balances.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130551-203045

+ Details

Name:	us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045

+ Details

Name:	us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration